SCHEMBL30238891

SCHEMBL30238891

CC(C)(C)OC(=O)N1CCC[C@H]1C(=O)NS(=O)(=O)N(CCCCCCOCCOCCNC(=O)OCc1ccccc1)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@@H]2OC(C)(C)O[C@@H]21

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DOT1L Q8TEK3 5/20 0.47
▸ RXFP1 Q9HBX9 1/20 0.39
▸ PI4KA P42356 1/20 0.38
▸ PI4K2B Q8TCG2 1/20 0.38
▸ PI4K2A Q9BTU6 1/20 0.38
▸ PI4KB Q9UBF8 1/20 0.38
▸ P2RX1 P51575 1/20 0.36
▸ P2RX3 P56373 1/20 0.36
▸ P2RX4 Q99571 1/20 0.36
▸ WDR5 P61964 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ RBBP5 Q15291 1/20 0.36
▸ DPY30 Q9C005 1/20 0.36
▸ ASH2L Q9UBL3 1/20 0.36
▸ AHCY P23526 1/20 0.36
▸ PRKACA P17612 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30238896 0.94 DOT1L (0.43) DOT1LRXFP1PI4KAPI4K2BPI4K2A
SCHEMBL30239020 0.89 RXFP1 (0.44) DOT1LRXFP1PI4KAPI4K2BPI4K2A
SCHEMBL30239396 0.87 DOT1L (0.57) DOT1LRXFP1PI4KAPI4K2BPI4K2A
SCHEMBL30239335 0.86 DOT1L (0.50) DOT1LRXFP1PI4KAPI4K2BPI4K2A
SCHEMBL31533318 0.84 DOT1L (0.48) DOT1LRXFP1PI4KAPI4K2BPI4K2A
SCHEMBL31533320 0.83 DOT1L (0.47) DOT1LRXFP1PI4KAPI4K2BPI4K2A
SCHEMBL30239717 0.82 DOT1L (0.50) DOT1LRXFP1PI4KAPI4K2BPI4K2A
SCHEMBL9970147 0.80 DOT1L (0.58) DOT1LRXFP1PI4KAPI4K2BPI4K2A
SCHEMBL30238902 0.79 DOT1L (0.65) DOT1LRXFP1PI4KAPI4K2BPI4K2A
SCHEMBL15598668 0.78 DOT1L (0.58) DOT1LRXFP1PI4KAPI4K2BPI4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250093263-A1 FRET-BASED ASSAYS THE GENERAL HOSPITAL CORPORATION 2025-03-20 — — US disclosed
EP-4374157-A2 FRET-BASED ASSAYS The General Hospital Corporation (US) 2024-05-29 — — EP disclosed
WO-2023004438-A2 FRET-BASED ASSAYS THE GENERAL HOSPITAL CORPORATION (US) 2023-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250093263-A1 FRET-BASED ASSAYS TARBP1, GTPBP4, TERF2IP DOT1L 3975/4885RXFP1 2124/4885PI4KA 2154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback